Heparanase plays a critical role in the degradation of extracellular matrix and cell membrane and is frequently upregulated in malignant tumors. Transcription factor, early growth response 1 (EGR1), is closely associated with inducible transcription of the heparanase gene. We hypothesized that promoter CpG hypomethylation with increased EGR1 expression could determine heparanase expression during the pathogenesis of bladder cancer. Bladder cancer cell lines (J82, T24 and transitional cell carcinoma) significantly restored heparanase expression after 5-AzadC treatment. Transfection of EGR1 siRNA with T24 bladder cancer cell line significantly downregulated heparanase expression compared to the control siRNA transfection. In 54 bladder cancer and paired normal bladder samples, heparanase expression was significantly higher in bladder cancer than in normal bladder (Po0.01). We performed methylation-specific PCR targeting the CpG sites within the core-binding consensus motifs of EGR1 (GGCG) and Sp1 (GGGCGG). Methylation prevalence was significantly higher in normal bladder than in bladder cancer (Po0.05) and inversely correlated with heparanase expression (P ¼ 0.055). In the total series of bladder cancer and normal bladder samples, the combination of promoter CpG methylation and EGR1 expression regulated heparanase expression in a stepwise manner, where heparanase expression was the lowest in methylation-positive and EGR1-negative samples and the highest in methylation-negative and EGR1-positive samples. To our knowledge, this is the first study demonstrating that increased heparanase expression during the pathogenesis of bladder cancer is due to promoter hypomethylation and transcription factor EGR1.
Introduction
Degradation of basement membrane as well as extracellular matrix (ECM) comprises an initial and essential step for cancer cells to invade surrounding tissue and metastasize to distant organs (Vlodavsky and Friedmann, 2001 ). Both the basement membrane and ECM contain heparan sulfite (HS) and heparan sulfate proteoglycans (HSPGs) as major structural components, which in turn serve as good substrates for heparanase (Hulett et al., 1999) . Therefore, heparanase, an endo-beta-D-glucuronidase, plays an important role in disassembling the ECM with the cooperation of matrix metalloproteinases (Sato et al., 2003) and urokinase-type plasminogen activator (Guo et al., 2002) . Heparanase activity is frequently upregulated in various cancers such as gastric (Takaoka et al., 2003) , pancreatic (Koliopanos et al., 2001) , melanoma (Marchetti et al., 1996) , prostate (Kosir et al., 1997) and bladder (Gohji et al., 2001) . In addition, several lines of evidence clearly demonstrate that overexpression of heparanase is correlated with increased metastatic potential and worse prognosis (Gohji et al., 2001; Koliopanos et al., 2001; Takaoka et al., 2003) . However, the mechanisms underlying heparanase overexpression in cancer cells remain unclear.
Epigenetic processes, marked by hypermethylation of the promoter region, contribute to the regulation of gene transcription (Ehrlich, 2002) . Its importance has been documented in the downregulation of tumor suppressor genes (Fujii et al., 1998) and DNA mismatch repair genes (Kanaya et al., 2003) during cancer development and progression. Also, the prevalence of genome-wide hypomethylation has been described in several cancers (Kaneda et al., 2004) and site-specific hypomethylation of the promoter region has been shown to upregulate the expression of cancer-promoting genes (Ehrlich, 2002) . Recently, promoter methylation has been associated with the regulation of heparanase expression in cancer cell lines (Shteper et al., 2003) . In addition to the active involvement of promoter methylation in heparanase regulation, early growth response 1 (EGR1), a member of the zinc-finger family of transcription factors, has been shown to be important in the inducible transcription of the heparanase gene (De Mestre et al., 2003) . The core binding motif of EGR1 (CCGC) has one CpG site within its sequence and is located within the proximal heparanase promoter region (De Mestre et al., 2003) . Taking these facts into consideration, we hypothesize that CpG hypomethylation of the heparanase promoter coupled with EGR1 levels are related to increased heparanase expression in human bladder cancer. To test this hypothesis, the methylation status of the heparanase promoter and expression of heparanase and EGR1 were analysed in bladder cancer cell lines and tissues (54 bladder cancer samples and 54 corresponding normal bladder samples) (Figure 1 ).
Results

Heparanase mRNA expression in bladder cancer cell lines and clinical samples
In the bladder cancer cell lines J82, T24 and transitional cell carcinoma (TCC), differential RT-PCR showed that 5 0 -Aza-dC treatment significantly upregulates heparanase mRNA transcripts in comparison with the control nontreated cell lines (Figure 2a ). In the UMUC cell line, there was no difference in expression of heparanase mRNA transcript before and after the 5 0 -Aza-dC treatment (Figure 2a ). These results suggested that heparanase mRNA expression is regulated by the epigenetic promoter CpG methylation. The RT-PCR results showed that expression of heparanase mRNA was positive in 21 bladder cancer samples (38.9%) and in six normal bladder samples (11.1%). Representative bladder cancer and normal bladder samples are shown in Figure 2b , where heparanase expression levels are higher in bladder cancer than in normal bladder samples. The difference in heparanase expression between bladder cancer and normal bladder reached statistical significance (Figure 2c ). No significant correlation of heparanase expression with histological grade or pT category was found, probably owing to the small number of cases studied.
Methylation status of the heparanase gene in bladder cancer and normal bladder samples
Typical results of methylation analysis are shown in Figure 3a . In bladder cancer samples, methylation at methylation-specific PCR (MSP)-A, MSP-B and MSP-C was positive in 16 cases (29.6%), 19 cases (33.3%) and 17 cases (31.5%), respectively. On the contrary, in normal bladder samples, methylation was positive in 38 cases (70.4%) of MSP-A, in 18 cases (35.2%) of MSP-B and in 28 cases (51.9%) of MSP-C. The frequency of methylation at MSP-A and MSP-C was significantly higher in normal bladder samples than in bladder cancer samples (Po0.01 and 0.05, respectively), whereas no significant difference in the frequency of MSP-B methylation was found between bladder cancer and normal bladder ( Figure 3b ). As shown in Figure 3c , an inverse correlation between methylation frequency and heparanase mRNA expression was found only in MSP-C (P ¼ 0.055), where the consensus binding motif of EGR1 was covered by reverse primers, but not found in MSP-A or MSP-B. In this study, there was no Figure 1 The proximal heparanase gene promoter and its relationship with methylation detection primers. Two different sets of universal primers (Pan1S and Pan1AS, and Pan2S and Pan2AS) were designed to amplify the proximal promoter region of the human heparanase gene (Jiang et al., 2002) . PCR products obtained from universal primers PCR1 and PCR2 were used as templates for a second round of nested PCR (MSP-A, MSP-B and MSP-C and corresponding USP-A, USP-B and USP-C, respectively). The universal primers contain no CpG sites within their sequence. Forward primers HPBM-S and HPBU-S contain the consensus motif for the Sp1-binding site (GGGCGG), while reverse primers HPCM-AS and HPCU-AS contain the consensus motif for the EGR1-binding site (GGCG). Primer sequences, annealing temperatures and expected product sizes are shown in Table 1 Heparanase expression in bladder cancer T Ogishima et al significant difference in the methylation status of MSP-A, MSP-B or MSP-C between superficial and invasive bladder cancers or between low-and high-grade bladder cancers.
Bisulfite genomic sequencing
Typical bisulfite DNA sequencing of bladder cancer and normal bladder samples are shown in Figure 4a and b, respectively. In normal bladder samples all CpG sites including the EGR1-binding motif as well as the Sp1 site were unmethylated, while in bladder cancer samples these CpG sites were partially or completely methylated ( Figure 4 ).
Combined effect of promoter methylation and EGR1 expression on heparanase expression
As shown in Figure 5a , correlation analysis revealed a significant association of EGR1 expression with heparanase expression in the total series of bladder cancer and normal bladder samples (Po0.01). This positive correlation of EGR1 expression with heparanase expression was also found in bladder cancer samples (Po0.05, data not shown), but not in normal bladder samples. Logistic regression analysis demonstrated that, in bladder cancer samples, EGR1 expression is more likely to contribute to heparanase expression than MSP-C; however, in normal bladder MSP-C is more significantly associated with heparanase expression than EGR1 expression ( Figure 5b ). As shown in Figure 5c , in the total series of bladder cancer and normal bladder, a stepwise increase in heparanase expression was observed, dependent on the combination between MSP-C methylation and EGR1 expression. Thus, heparanase expression was lowest in the group of MSP-C-positive and EGR1-negative samples and highest in the group of MSP-Cnegative and EGR1-positive samples. However, EGR1 expression was not significantly higher in bladder cancer than in normal tissue and no significant relationship was observed between EGR1 expression and pathological findings (data not shown).
RNAi using EGR1 siRNA inhibits heparanase expression in bladder cancer cell lines
To confirm whether or not endogenous EGR1 can directly regulate heparanase gene expression in T24 bladder cancer cells, we used siRNA targeting EGR1 ( Figure 6 ). RT-PCR analysis was performed on extracts prepared 48 h after transfection. The means and standard errors of triplicate measurements are shown in Figure 6b . The EGR1 siRNA (siEGR) led to a significant reduction of EGR1 mRNA levels without reduction of G3PDH mRNA expression as compared to the control siRNA (siControl) (Figure 6a ). EGR1 knockdown by siEGR1 also caused the downregulation of heparanase mRNA expression (Po0.05). These results further confirm that EGR1 is one of the important factors that directly modulates heparanase transcriptional activity. 
Discussion
Heparanase is an enzyme that is actively involved in the process of tumor invasion, metastasis and tumor neovascularization (Vlodavsky and Friedmann, 2001 ). In bladder cancer, expression of mRNA transcript of heparanase gene is increased along with tumor invasiveness (Gohji et al., 2001) . Also, heparanase has been frequently overexpressed in various malignant tumors (Marchetti et al., 1996; Gohji et al., 2001; Koliopanos et al., 2001; Takaoka et al., 2003) ; however, the mechanism underlying overexpression of heparanase in malignant tumors remains unclear. To address this issue, we analysed bladder cancer samples as targets of investigation to clarify the mechanisms involved in the overexpression of heparanase. Recent reports have shown that overexpressed heparanase protein in highly invasive and/or metastatic tumors is closely related to upregulation of heparanase gene (Gohji et al., 2001; Koliopanos et al., 2001; Takaoka et al., 2003) , indicating that the mechanisms underlying increased expression of heparanase at the transcriptional level could provide a better understanding of the functional regulation of heparanase gene in bladder cancer.
The heparanase gene locus on chromosome 4q is seldom affected by genetic events such as gene amplification in bladder cancer (Simon et al., 1998; Hurst et al., 2004) . We hypothesized that heparanase gene is regulated by epigenetic CpG promoter methylation. In the current study, three (J82, T24, TCC) out of four bladder cancer cell lines showed increases in the levels of heparanase mRNA transcripts after 5 0 -Aza-dC Logistic regression analysis indicated that EGR1 expression was more significantly associated with heparanase expression than MSP-C methylation in the total series of bladder cancer samples. In contrast, MSP-C contributes more significantly to heparanase expression than EGR1 expression in normal bladder samples. (c) A stepwise increase in heparanase expression was dependent on the combined effects of MSP-C methylation and EGR1 expression in the total series of bladder cancer and normal bladder samples. Heparanase expression was lowest in MSP-C-positive and EGR1-negative samples and highest in MSP-C-negative and EGR1-positive samples. We applied the cutoff value of EGR1 expression, which was the average value (AUs) of EGR mRNA expression in normal bladder samples, and separated EGR1-positive and -negative samples
Heparanase expression in bladder cancer T Ogishima et al treatment, suggesting that promoter methylation could be involved in the transcriptional regulation of the heparanase gene (Shteper et al., 2003) . Based on the functional promoter sequence of heparanase gene (De Mestre et al., 2003) , MSP and USP primers were specifically designed to analyse the difference in promoter CpG methylation between normal bladder and bladder cancer. Several important consensus transcription factor binding sites are present within the heparanase gene promoter, that is, Sp1 contributes to basal transcription of heparanase (Jiang et al., 2002) , and the EGR1 site is essential for its inducible transcription (De Mestre et al., 2003) . EGR1 is a zinc-finger transcription factor found in smooth muscle cells (Silverman et al., 1997) and endothelial cells (Khachigian et al., 1996) . Recent publications have shown that EGR1 is frequently overexpressed in prostate cancer (Adamson et al., 2003) and actively involved in the pathogenesis of prostate cancer (Abdulkadir et al., 2001) . The putative EGR1-binding site within the heparanase promoter is GTGAGGAGGCGT (De Mestre et al., 2003) , in which one CpG site (GGCG) is present. In the current study, expression of heparanase mRNA transcripts was higher in bladder cancer than in normal bladder and this increase was inversely correlated with MSP-C methylation, but not with MSP-A or MSP-B methylation. We also found that MSP-C methylation is a more frequent epigenetic event in normal bladder than in bladder cancer (Figure 5b) . Based on the primer locations shown in Figure 1 , a high prevalence of MSP-C methylation in normal bladder might reflect a high prevalence of methylation in the region of the EGR1/Sp1-binding site. Taken together, we hypothesize that both promoter hypomethylation and EGR1 expression are key events that cause increased heparanase expression in bladder cancer.
In support of this hypothesis, a positive correlation between heparanase expression and EGR1 expression was found in bladder cancer (Figure 5a ), but not in normal bladder. Logistic regression analysis also revealed that the contribution of EGR1 expression to heparanase expression is less significant in normal bladder, in which high prevalence of promoter methylation was found, than in bladder cancer (Figure 5b ). In addition, as shown in Figure 5c , a stepwise increase in heparanase expression was associated with combined effects of MSP-C methylation and EGR1 expression in the total series of bladder cancer and normal bladder. These findings clearly suggest that enhanced heparanase expression in bladder cancer is related to at least two different but concomitant events, escape from hypermethylation and increased binding of EGR1 during the pathogenesis of bladder cancer. Moreover, in order to determine whether endogenous EGR1 directly regulates heparanase gene expression, we targeted EGR1 with a specific siRNA in a bladder cancer cell line (Figure 6 ). These data clearly demonstrated that EGR1 is an important transcription factor that directly regulates heparanase gene expression in bladder cancer. Our result is consistent with the finding observed in T cells (De Mestre et al., 2003) and prostate cancer (Ogishima et al., 2005) . Unlike prostate cancer (Ogishima et al., 2005) , EGR1 expression was not significantly higher in bladder cancer than in normal tissue (data not shown). Again, our results indicate that hypomethylation facilitates EGR1 binding to its consensus motif and escape from methylation may be an important first step for heparanase expression in bladder cancer. Recently, in gastric cancer, monoallelic de-methylation of the maspin promoter has been reported to be associated with transcriptional upregulation of maspin expression (Akiyama et al., 2003) . However, we did not investigate the significance of allele-specific methylation of the heparanase promoter in bladder samples. Further studies are warranted to confirm the effect of allele-specific methylation on heparanase expression in bladder cancer.
In conclusion, to our knowledge this is the first comprehensive study demonstrating that increased heparanase expression in human bladder cancer occurs by hypomethylation of the heparanase gene promoter concomitant with binding of transcription factor EGR1.
Materials and methods
Bladder cancer samples
In all, 54 samples of primary TCC and corresponding normal bladder mucosa were obtained by either total cystectomy or transurethral resection of bladder cancer (TUR-Bt) at the Shimane University School of Medicine. These samples were staged according to the TNM classification and graded histologically (Sobin et al., 2002) . The mean age of the patients (44 males and 10 females) was 62 years old (44-90). The bladder cancer cohort included 36 cases of superficial (pTapT1) and 18 of invasive (pT2-pT4) bladder cancer, 28 cases of Grades 1 and 2, and 26 cases of Grade 3 bladder cancer. Each tissue sample was fixed in 10% buffered formalin (pH 7.0) and embedded in paraffin wax. Sections (5 mm) were used for hematoxylin and eosin staining for histological evaluation. Snap-frozen samples were stored at À801C until analysed.
Cell lines
Human urinary bladder cancer cell lines, J82, T24, TCC and UMUC, were obtained from the American Type Culture Collection (Rockville, MD, USA). Cell lines were cultured in 5A McCoy's with 10% regular FBS and antibiotics (100 U/ml penicillin and 100 mg/ml streptomycin), and were maintained in a humidified atmosphere of 5% CO 2 /95% air at 371C.
Nucleic acid extraction
Genomic DNA was extracted from bladder tumor and normal bladder samples using a Qiagen kit (Qiagen, Valencia, CA, USA) after microdissection (Dahiya et al., 1997) . Total RNA was isolated using Isogen reagent (Nippon Gene, Tokyo, Japan). The RNA pellet obtained after isopropanol and ethanol precipitation was dried and re-suspended in 50 ml of RNase-free water. All RNA specimens were subjected to DNase treatment (Wako Pure Chemical, Osaka, Japan) and stored in aliquots at À801C until reverse transcribed. The concentrations of DNA and RNA were determined with a spectrophotometer and their integrity was assessed by gel electrophoresis.
5-Aza-dC treatment
Cell lines (J82, T24, TCC and UMUC) cultured in 5A McCoy's with 10% regular FBS were treated with 5-Aza-dC (10 mM) in duplicate to screen for epigenetic alterations and harvested after 3 days of treatment. Using cDNAs obtained from bladder cancer cell lines, mRNA transcripts of heparanase before and after 5-Aza-dC treatment were analysed by RT-PCR.
cDNA preparation and RT-PCR analysis
The cDNA was prepared by reverse transcription (Promega Corp., Madison, WI, USA) using DNase-treated RNA as a template. Samples were stored at À201C until used. The HepaRT1 and HepaRT2 primers were designed to detect heparanase gene expression. For differential RT-PCR, G3PDH1 primer (150 nM each) and HepaRT1 primer (200 nM each) for cell line cDNA or G3PDH2 primer (100 nM each) and HepaRT2 primer (150 nM each) for clinical sample cDNA were used. An annealing temperature of 551C was used for PCR reactions, with 26 cycles for cell line samples and 28 cycles for clinical samples. The PCR products were electrophoresed in 2.0% agarose gels and expression levels evaluated by ImageJ software (http://rsb.info.nih.gov/ij). The areas under the curves were calculated, analysed and used to determine levels of heparanase relative to G3PDH levels and expressed as arbitrary units (AUs).
Methylation-specific PCR
Genomic DNA (1 mg) was modified with sodium bisulfite using a commercial kit (Invitrogen, Carlsbad, CA, USA). Complete conversion of 'C' to 'T' by sodium bisulfite modification was verified using the method developed in our laboratory (Sasaki et al., 2003) . Based on the functional promoter sequence of the heparanase gene (Jiang et al., 2002) , several sets of primers were designed to detect the methylation status of CpG sites using the MethPrimer program (http://itsa.ucsf.edu/~urolab/ methprimer). Modified DNA (10 ng) was used for MSP reactions. The amplified region covered by Pan1S and Pan2AS, in which 37 CpG sites are present, and primer locations in relation to the CpG sites are shown in Figure 1 . For MSP, a second round of nested PCR (MSP-A, MSP-B and MSP-C) was performed using universal PCR products (universal PCR1 or PCR2) as templates. The first universal primer sets (Pan1S, Pan1AS, Pan2S and Pan2AS) cover no CpG sites in either the forward or reverse primer. However, the HPBM-S and HPBU-S primer covers the Sp1 site, while the HPCM-AS and HPCU-AS primer covers both the EGR1 and Sp1/Ets sites. In each assay, the absence of DNA template served as a negative control. All of the PCRs were repeated at least twice. The primer sequences are shown in Table 1 . The cycle number of first step PCR was 35 cycles and second PCR was 25 cycles. The PCR products were separated by electrophoresis in a 3% agarose gel containing ethidium bromide and DNA bands were visualized by ultraviolet light.
siRNA treatment T24 bladder cancer cells (1 Â 10 5 ) were plated overnight in sixwell plates in 5A McCoy's medium with 10% regular FBS and without antibiotics. They were transiently transfected either with EGR1 siRNA or control siRNA (Invitrogen, Carlsbad, CA, USA) using lipofectamine 2000 transfection reagent as described by the manufacturer (Invitrogen, Carlsbad, CA, USA). The cell lysates were harvested 2 days after transfection. Total RNA was prepared from T24 cells transfected with siRNA, and EGR1 expression and heparanase expression was evaluated by RT-PCR as described above. Sequences of EGR1 siRNA and control siRNA are 5 0 -CCAUGGACAA CUACCCUAA [dT] [dT]-3 0 and 5 0 -ACUUACGAGUGACA GUAGA [dT] [dT]-3 0 , respectively.
Bisulfite DNA sequencing
Bisulfite-modified DNA (10 ng) was amplified using a pair of universal primers (Pan-S and Pan-AS) in a total volume of 20 ml. Direct bisulfite DNA sequencing of the PCR products using either forward universal primer (Pan1S or Pan2S) or reverse primer (Pan1AS or Pan2AS) was performed according to the manufacturer's instructions (Applied BioSystem, Foster City, CA, USA).
Statistical analysis
Statistical analysis was performed using the w 2 test or logistic regression analysis. The correlation between two continuous variables was analysed by either Pearson's coefficient correlation or Spearman's rank correlation. A P-value of less than 0.05 was regarded as statistically significant. 
